What is deferasirox used for?

Indications and Usage, quoted from the label by Teva Pharmaceuticals, Inc. (ANDA207124). Cross-references to other label sections are left out.

Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload)

Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes

Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L.

Limitations of Use

The safety and efficacy of deferasirox when administered with other iron chelation therapy have not been established.

Source: DailyMed label, set id e9054806-2721-4736-9aef-81ffb8db75d1, version 8, effective July 1, 2024. NDC 0480-7011, one of 30 listings for this product.

Indications and Usage, quoted from the label by Camber Pharmaceuticals, Inc. (ANDA214341). Cross-references to other label sections are left out.

Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload)

Deferasirox tablets are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes

Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L.

Limitations of Use

The safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established.

Source: DailyMed label, set id 65453013-c360-4835-8358-2a278a4a32db, version 3, effective February 11, 2025. NDC 31722-011, one of 27 listings for this product.

Indications and Usage, quoted from the label by Aurobindo Pharma Limited (ANDA215137). Cross-references to other label sections are left out.

Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload)

Deferasirox oral granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes

Deferasirox oral granules are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L.

Limitations of Use

The safety and efficacy of deferasirox oral granules when administered with other iron chelation therapy have not been established.

Source: DailyMed label, set id c220484e-1e6a-4a0c-a221-60223f3bc24c, version 1, effective September 9, 2025. NDC 59651-447, one of 18 listings for this product.